Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.30 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL767567 | 0.93 | HRH3 (0.33) | — | |
| SCHEMBL767673 | 0.91 | HSD11B1 (0.32) | NPC1 | |
| SCHEMBL767618 | 0.90 | NPC1 (0.30) | NPC1 | |
| SCHEMBL767666 | 0.88 | SYK (0.35) | POLB | |
| SCHEMBL767539 | 0.88 | — | — | |
| SCHEMBL767641 | 0.88 | — | — | |
| SCHEMBL767688 | 0.87 | SYK (0.34) | POLB | |
| SCHEMBL767677 | 0.85 | PIM1 (0.31) | — | |
| SCHEMBL767515 | 0.83 | KDM4E (0.36) | — | |
| SCHEMBL767768 | 0.80 | TDP1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160348110-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-9453043-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | BANK OF AMERICA, N.A. | 2015-07-30 | — | — | US | disclosed |
| US-8975389-B2 | Nucleic acid chemical modifications | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210733-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | NPC1 1403/4885POLB 86/4885PSMB1 1546/4885 |
| US-20120071641-A1 | NUCLEIC ACID CHEMICAL MODIFICATIONS | NSUN2, RNMT, NSUN3 | NPC1 1409/4885POLB 102/4885PSMB1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.